The 36-month beta value for CRGX is at 0.73. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 7 as “hold,” and 0 as “sell.”
The public float for CRGX is 30.19M, and currently, shorts hold a 11.24% of that float. The average trading volume for CRGX on March 19, 2025 was 992.55K shares.
CRGX) stock’s latest price update
CARGO Therapeutics Inc (NASDAQ: CRGX)’s stock price has gone decline by -7.54 in comparison to its previous close of 4.11, however, the company has experienced a -3.06% decrease in its stock price over the last five trading days. globenewswire.com reported 2025-03-18 that – Development of CRG-023 and allogeneic platform suspended; further reduction in force (RIF) of approximately 90% to preserve cash and maximize shareholder value – – CARGO had cash, cash equivalents and marketable securities of $368.1 million as of December 31, 2024 – – Anup Radhakrishnan appointed as interim CEO to pursue reverse merger or other business combination – SAN CARLOS, Calif., March 18, 2025 (GLOBE NEWSWIRE) — CARGO Therapeutics, Inc. (Nasdaq: CRGX) today provided an update regarding its ongoing evaluation of strategic options following the discontinuation of FIRCE-1, a Phase 2 study of firicabtagene autoleucel (firi-cel).
CRGX’s Market Performance
CRGX’s stock has fallen by -3.06% in the past week, with a monthly rise of 2.70% and a quarterly drop of -74.56%. The volatility ratio for the week is 5.87% while the volatility levels for the last 30 days are 5.96% for CARGO Therapeutics Inc The simple moving average for the past 20 days is -2.38% for CRGX’s stock, with a -74.88% simple moving average for the past 200 days.
Analysts’ Opinion of CRGX
Truist, on the other hand, stated in their research note that they expect to see CRGX reach a price target of $7, previously predicting the price at $32. The rating they have provided for CRGX stocks is “Hold” according to the report published on January 30th, 2025.
Piper Sandler gave a rating of “Neutral” to CRGX, setting the target price at $4 in the report published on January 30th of the current year.
CRGX Trading at -45.62% from the 50-Day Moving Average
After a stumble in the market that brought CRGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.41% of loss for the given period.
Volatility was left at 5.96%, however, over the last 30 days, the volatility rate increased by 5.87%, as shares surge +2.70% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -74.75% lower at present.
During the last 5 trading sessions, CRGX fell by -3.06%, which changed the moving average for the period of 200-days by -78.94% in comparison to the 20-day moving average, which settled at $3.89. In addition, CARGO Therapeutics Inc saw -73.65% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRGX starting from Chapman Gina, who sale 7,166 shares at the price of $25.09 back on Sep 18 ’24. After this action, Chapman Gina now owns 103,905 shares of CARGO Therapeutics Inc, valued at $179,775 using the latest closing price.
Chapman Gina, the President & CEO of CARGO Therapeutics Inc, sale 2,975 shares at $25.03 during a trade that took place back on Sep 19 ’24, which means that Chapman Gina is holding 103,905 shares at $74,457 based on the most recent closing price.
Stock Fundamentals for CRGX
The total capital return value is set at -0.48. Equity return is now at value -69.81, with -57.80 for asset returns.
Based on CARGO Therapeutics Inc (CRGX), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -4.75.
Currently, EBITDA for the company is -187.37 million with net debt to EBITDA at 0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 18.95.
Conclusion
In conclusion, CARGO Therapeutics Inc (CRGX) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
